AnaptysBio, which is developing antibody products focused on inflammation and immuno-oncology, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The San Diego, CA-based company, which was founded in 2005 and booked $19 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol ANAB. BMO Capital Markets and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
